Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Studies: HPV May be a Cause of Skin Cancer; CBCD Reviews the Studies and Recommends Two Natural HPV Remedies
  • USA - English


News provided by

CBCD

Dec 29, 2014, 00:00 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) December 29, 2014 -- “Infected with the human papillomavirus (HPV)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” – Greg Bennett, CBCD

A history of blistering sunburn was associated with prevalent and persistent HPV infection - PLoS One (2)

Post this

Medical studies now show that the human papillomavirus (HPV) is associated with skin cancer. As Dr. Shalaka Hampras recently wrote in a study published in PLoS One, “evidence suggests that cutaneous human papillomavirus (HPV) infection is associated with non-melanoma skin cancer (NMSC).” (See PLoS One, from September 8, 2014) (2) Dr. Hampras is from the Department of Cancer Epidemiology at the Moffitt Cancer Center in Tampa, Florida.

The main cause of non-melanoma skin cancer is exposure to ultraviolet (UV) radiation. However, Dr. Accadi agrees with Dr. Hampras, writing in another study that, “cutaneous HPVs that belong to the beta genus may act as a co-carcinogen with UVR (ultraviolet radiation) ... Beta-HPVs may also play a role in cutaneous Sub Cutaneous Carcinoma in immunocompromised ... and in immunocompetent individuals.” (1) Dr. Accadi is from the Infections and Cancer Biology (ICB) Group at the International Agency for Research on Cancer with the World Health Organization.

Cutaneous warts appear commonly among certain occupations “such as handlers of meat, poultry, and fish.” (See Uptodate.com, last updated April 4, 2014) (3) Predisposing conditions for wart development include: “atopic dermatitis and any condition in which there is decreased cell-mediated immunity.” (3) Infection with HPV “occurs by skin-to-skin contact ... latent HPV infection also may occur in normal skin.” (3)

The Center for the Biology of Chronic Disease (CBCD) recommends that individuals infected with HPV take Novirin or Gene-Eden-VIR. The formula of these natural HPV remedies was shown to reduce HPV symptoms in two separate, post-marketing clinical studies that followed FDA guidelines.

Click to learn more about HPV symptoms.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (4) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Scientists have discovered that “older age was significantly associated with prevalent (widespread) and persistent (long-term, chronic) HPV infection. History of blistering sunburn was associated with prevalent and persistent HPV infection ... cutaneous HPV is highly prevalent in men, with age and blistering sunburn being significant risk factors for cutaneous HPV infection.” (2)

What if an individual has already been vaccinated against HPV?

“The HPV vaccine is most effective before a person is infected with an HPV … the vaccine cannot protect against established infection, nor does it protect against all types of HPV.” (See WebMD, last reviewed October 28, 2010) (5).

Are there drugs that work against the HPV virus?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (4) In contrast, Novirin and Gene-Eden-VIR were designed to target the latent HPV.

“We recommend that individuals infected with HPV take Novirin or Gene-Eden-VIR against the latent virus. The formula of these natural antiviral products was designed to help the immune system target the virus while in a latent state.” – Greg Bennett, CBCD

Click to read more about Novirin and the HPV, or Gene-Eden-VIR and the HPV.

References:

(1) Accardi R1, Gheit T2. "Cutaneous HPV and skin cancer." Presse Medicale. Published on October 22, 2014.
http://www.ncbi.nlm.nih.gov/pubmed/25451638

(2) Shalaka S. Hampras,1 Anna R. Giuliano,1 Hui-Yi Lin,2 Kate J. Fisher,2 Martha E. Abrahamsen,1 Bradley A. Sirak,1 Michelle R. Iannacone,3 Tarik Gheit,4 Massimo Tommasino,4 and Dana E. Rollison1,* "Natural History of Cutaneous Human Papillomavirus (HPV) Infection in Men: The HIM Study." PLoS One. Published on September 8, 2014.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157763/

(3) Uptodate.com - Cutaneous Warts. Last Updated April 4, 2014.
http://www.uptodate.com/contents/cutaneous-warts

(4) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VJmbCsAk

(5) WebMD.com - Women's Health - "Cervical Cancer: A Shot of Prevention." Last reviewed October 28, 2010
http://www.webmd.com/women/features/cervical-cancer-shot-prevention?query=

Greg Bennett, CBCD, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.